Zoetis Inc. $ZTS Shares Acquired by Bank OZK

Bank OZK lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 702.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,567 shares of the company’s stock after acquiring an additional 11,877 shares during the period. Bank OZK’s holdings in Zoetis were worth $2,234,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Brighton Jones LLC raised its position in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $216,000. First Trust Advisors LP raised its position in shares of Zoetis by 134.8% during the 4th quarter. First Trust Advisors LP now owns 104,496 shares of the company’s stock valued at $17,026,000 after acquiring an additional 59,990 shares in the last quarter. Capital Research Global Investors acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $178,688,000. Finally, Natixis grew its stake in Zoetis by 76.4% during the 4th quarter. Natixis now owns 59,681 shares of the company’s stock worth $9,724,000 after buying an additional 25,856 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company’s stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ZTS shares. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and an average price target of $202.43.

Zoetis Trading Down 1.2%

NYSE:ZTS opened at $152.28 on Tuesday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market cap of $67.49 billion, a price-to-earnings ratio of 26.21, a PEG ratio of 2.47 and a beta of 0.88. The business has a fifty day moving average of $154.69 and a 200-day moving average of $158.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.3%. Zoetis’s dividend payout ratio is presently 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.